These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 10889820)

  • 1. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
    Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
    J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.
    Press MF; Slamon DJ; Flom KJ; Park J; Zhou JY; Bernstein L
    J Clin Oncol; 2002 Jul; 20(14):3095-105. PubMed ID: 12118023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay.
    Goud KI; Dayakar S; Vijayalaxmi K; Babu SJ; Reddy PV
    Indian J Med Res; 2012 Mar; 135(3):312-7. PubMed ID: 22561616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.
    Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
    J Clin Oncol; 1999 Jul; 17(7):1974-82. PubMed ID: 10561247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
    Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
    J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D; Di Leo A; Rouas G; Paesmans M; Ferreira-Filho F; Bernard C; Cardoso F; Verhest A; Piccart MJ; Gancberg D
    Anticancer Res; 2002; 22(4):2485-90. PubMed ID: 12174949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular protocol for HER2/neu analysis in breast carcinoma].
    Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
    Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
    Lal P; Salazar PA; Ladanyi M; Chen B
    J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.